BMS' top drug faces patent challenge

Share this article:
The FDA approved a Canadian company’s application to produce a generic version of Bristol-Myers Squibb’s best-selling drug Plavix. The approval means generic maker Apotex could bring a generic form of the heart medication to market before a key Plavix patent expires in 2011. However, BMS and Sanofi-Aventis have sued Apotex over the validity and enforceability of the patent. A federal trial is scheduled for April. BMS “continues to believe that the patent is valid and that it is infringed, and with its alliance partner and patent-holder Sanofi-Aventis, is vigorously pursuing these cases,” BMS said in a statement. If the patent is held invalid, Apotex -- the first generic to file with the FDA -- stands to gain 180 days of generic market exclusivity on clopidogrel bisulfate. Plavix had 2005 US net sales of $3.2 billion.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.